by | Jul 27, 2015 | Uncategorized

Accuray Products Received Highest Composite User Satisfaction Ratings in Latest MD Buyline Report

User Satisfaction Ratings Consistently Exceeded Industry Average for the Past Two Years

SUNNYVALE, Calif., July 27, 2015 /PRNewswire/ — Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems have received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q2 2015 MD Buyline Market Intelligence Briefing™.

The most recent ratings trend also shows Accuray has achieved the highest ratings among industry peers over the past two years.

In rating Accuray, MD Buyline reports the company obtained the highest scores in all categories measured including system performance, system reliability, installation/implementation, application training and system response.

CyberKnife and TomoTherapy System users continue to report Accuray products as “user-friendly” and “highly reliable,” with system downtimes being “rare.”

Accuray personnel also received strong marks with customers praising, “their knowledge and ability to effectively communicate” with them.

“We set a goal of earning customer trust in our ability to deliver technological excellence and superior service.

The independent MD Buyline report provides tangible evidence we are delivering on this goal and reinforces our focus on customer satisfaction, which will always be of paramount importance to us,” said Joshua H. Levine, president and CEO of Accuray.

“The feedback also supports the changes we are seeing in the marketplace where customers are increasingly choosing the TomoTherapy System as their workhorse radiation oncology device, delivering excellent tumor control with low toxicities for more and more patients and disease types, and the CyberKnife System as the gold standard in full-body radiosurgery, enabling precise, high-quality dose distributions to be administered with extreme accuracy over a minimum number of treatments.”

MD Buyline, an independent market intelligence organization for the healthcare industry, measures linear accelerator user satisfaction based on evaluations by more than 3,300 hospitals in its member network that use the product every day.

Respondents rate how satisfied they are with products from Accuray, Elekta and Varian, using key metrics listed above along with installation and implementation, applications training, and service repair quality.

The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs.

The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients’ quality of life.

The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy® H™ Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types.

Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray:
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives.

The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

Safe Harbor Statement:
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements in this press release relate, but are not limited, to future growth, market success, adoption of our new products or services, benefits of our technologies, and Accuray’s leadership position in radiation oncology innovation and technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 29, 2014, the company’s reports on Form 10-Q, filed on November 7, 2014, February 6, 2015 and May 7, 2015, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events.

The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

To view the original version on PR Newswire, visit:
SOURCE Accuray Incorporated

(MD Buyline User Satisfaction Ratings, MD Buyline Market Intelligence Briefing™ Q2 2015) © 2015 MD Buyline, All Rights Reserved.  Used with Permission July 22, 2015.
About the CyberKnife and TomoTherapy Systems